12.13.25 -- Outsourced Pharma Best Of November

The most complex and expensive drugs to develop often target terrible diseases that affect only a small number of people and will never reach blockbuster status.

Artificial intelligence, even in its current form, is especially good at synthesizing large data sets. Here's how one company makes the most of it.

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.

Discover the full benefits of terminal sterilization, how it differs from aseptic manufacturing, and its level of compatibility with your product. Case study included.

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

The greatest challenge in drug development can be finding a team capable of carrying a molecule through the complexities that lie between the research lab and the patient’s bedside.